vs
梯瓦制药（INM）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
Arcadia Biosciences, Inc.的季度营收约是梯瓦制药的1.1倍（$901.0K vs $820.2K），Arcadia Biosciences, Inc.净利率更高（-148.3% vs -247.3%，领先99.0%），Arcadia Biosciences, Inc.同比增速更快（-25.8% vs -26.2%），过去两年Arcadia Biosciences, Inc.的营收复合增速更高（-4.5% vs -16.4%）
梯瓦制药工业有限公司是一家总部位于以色列的跨国制药企业，核心业务以仿制药研发生产为主，同时也布局品牌药、原料药生产领域，还少量开展合同生产服务以及对外授权业务，是全球知名的制药集团。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
INM vs RKDA — 直观对比
营收规模更大
RKDA
是对方的1.1倍
$820.2K
营收增速更快
RKDA
高出0.4%
-26.2%
净利率更高
RKDA
高出99.0%
-247.3%
两年增速更快
RKDA
近两年复合增速
-16.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $820.2K | $901.0K |
| 净利润 | $-2.0M | $-1.3M |
| 毛利率 | 22.5% | 21.4% |
| 营业利润率 | -247.3% | -152.8% |
| 净利率 | -247.3% | -148.3% |
| 营收同比 | -26.2% | -25.8% |
| 净利润同比 | 21.2% | 67.1% |
| 每股收益（稀释后） | $-0.51 | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INMRKDA
| Q4 25 | $820.2K | $901.0K | ||
| Q3 25 | $1.1M | $1.3M | ||
| Q2 25 | $1.3M | $1.5M | ||
| Q1 25 | $1.3M | $1.2M | ||
| Q4 24 | $1.1M | $1.2M | ||
| Q3 24 | $1.3M | $1.5M | ||
| Q2 24 | $1.3M | $1.3M | ||
| Q1 24 | $1.2M | $987.0K |
净利润INMRKDA
| Q4 25 | $-2.0M | $-1.3M | ||
| Q3 25 | $-1.7M | $856.0K | ||
| Q2 25 | $-1.8M | $-4.5M | ||
| Q1 25 | $-2.1M | $2.6M | ||
| Q4 24 | $-2.6M | $-4.1M | ||
| Q3 24 | $-1.7M | $-1.6M | ||
| Q2 24 | $-1.9M | $1.1M | ||
| Q1 24 | $-1.7M | $-2.4M |
毛利率INMRKDA
| Q4 25 | 22.5% | 21.4% | ||
| Q3 25 | 36.0% | 32.1% | ||
| Q2 25 | 44.2% | 43.4% | ||
| Q1 25 | 13.9% | 43.2% | ||
| Q4 24 | 41.5% | 31.9% | ||
| Q3 24 | 39.0% | 32.9% | ||
| Q2 24 | 36.3% | 51.5% | ||
| Q1 24 | 24.7% | 52.3% |
营业利润率INMRKDA
| Q4 25 | -247.3% | -152.8% | ||
| Q3 25 | -154.2% | -88.5% | ||
| Q2 25 | -137.1% | -34.4% | ||
| Q1 25 | -168.1% | 44.2% | ||
| Q4 24 | -231.6% | -187.7% | ||
| Q3 24 | -132.7% | -114.5% | ||
| Q2 24 | -150.5% | — | ||
| Q1 24 | -146.9% | -160.9% |
净利率INMRKDA
| Q4 25 | -247.3% | -148.3% | ||
| Q3 25 | -154.2% | 65.7% | ||
| Q2 25 | -137.1% | -306.4% | ||
| Q1 25 | -168.1% | 216.6% | ||
| Q4 24 | -231.6% | -334.5% | ||
| Q3 24 | -132.7% | -104.9% | ||
| Q2 24 | -151.0% | 81.2% | ||
| Q1 24 | -146.9% | -245.5% |
每股收益（稀释后）INMRKDA
| Q4 25 | $-0.51 | $-0.97 | ||
| Q3 25 | $-0.44 | $0.62 | ||
| Q2 25 | $-0.07 | $-3.26 | ||
| Q1 25 | $-1.94 | $1.90 | ||
| Q4 24 | $-3.64 | $-2.99 | ||
| Q3 24 | $-2.71 | $-1.18 | ||
| Q2 24 | $2.39 | $0.78 | ||
| Q1 24 | $-3.58 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.0M | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.6M | $4.1M |
| 总资产 | $11.2M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资INMRKDA
| Q4 25 | $7.0M | $4.6M | ||
| Q3 25 | $9.4M | $5.9M | ||
| Q2 25 | $11.1M | $4.4M | ||
| Q1 25 | $4.7M | $3.2M | ||
| Q4 24 | $3.5M | $4.2M | ||
| Q3 24 | $5.6M | $6.6M | ||
| Q2 24 | $6.6M | $8.1M | ||
| Q1 24 | — | $8.5M |
股东权益INMRKDA
| Q4 25 | $9.6M | $4.1M | ||
| Q3 25 | $11.6M | $5.4M | ||
| Q2 25 | $13.4M | $4.5M | ||
| Q1 25 | $7.0M | $8.9M | ||
| Q4 24 | $6.2M | $6.2M | ||
| Q3 24 | $8.4M | $10.3M | ||
| Q2 24 | $9.2M | $11.7M | ||
| Q1 24 | $11.1M | $10.6M |
总资产INMRKDA
| Q4 25 | $11.2M | $6.5M | ||
| Q3 25 | $13.4M | $8.6M | ||
| Q2 25 | $15.6M | $7.8M | ||
| Q1 25 | $9.3M | $13.0M | ||
| Q4 24 | $8.5M | $13.5M | ||
| Q3 24 | $10.5M | $15.2M | ||
| Q2 24 | $11.8M | $17.4M | ||
| Q1 24 | — | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.4M | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流INMRKDA
| Q4 25 | $-2.4M | $-861.0K | ||
| Q3 25 | $-1.6M | $-257.0K | ||
| Q2 25 | $-1.8M | $-2.0M | ||
| Q1 25 | $-1.7M | $-1.6M | ||
| Q4 24 | $-2.5M | $-2.2M | ||
| Q3 24 | $-1.8M | $-1.8M | ||
| Q2 24 | $-1.0M | $-2.5M | ||
| Q1 24 | $-1.9M | $-3.2M |
自由现金流INMRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-2.5M | ||
| Q1 24 | $-1.9M | $-3.2M |
自由现金流率INMRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -188.3% | ||
| Q1 24 | -165.0% | -326.5% |
资本支出强度INMRKDA
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | 0.0% | 1.3% |
现金转化率INMRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
